← Leaderboards
Matthias Schnell
Thomas Jefferson University
$21,800,660
Attributed
$21,800,660
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $6.8M · FY2018–23$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$21,800,660 · 1
By mechanism
N01$21,800,660 · 1
Top collaborators
No co-investigators on record.
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Flemming Forsberg$18,638,328
- Jay L Rothstein$12,595,060
- Joseph E Rabinowitz$3,593,996
- James P McGettigan$4,864,002
- Sudha Anupindi$1,012,151
Others in their field
Other Emerging Leaders on “Vaccines”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$149,372,007
- Kimberly Smith · Ppd Development Lp$115,671,664
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
- Yunda Huang · Fred Hutchinson Cancer Center$74,099,786
- Ted Ross · University Of Georgia$71,962,304
Research focus
VaccinesContractsDoseEbola VaccinesEfficacy TestingFilovirusFormulationToxicologyVaccine CandidateAdvanced DevelopmentImmunogenicityLassa FeverNonhuman PrimateResearch Clinical TestingStability TestingFrankfurt-Marburg Syndrome VirusMarburgvirusManufacture
Grant awards (6)
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$981,197
N01 · FY2023 · AI · contact PI
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$3,413,667
N01 · FY2022 · AI · contact PI
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$1,272,259
N01 · FY2021 · AI · contact PI
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$4,515,928
N01 · FY2020 · AI · contact PI
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$6,784,550
N01 · FY2019 · AI · contact PI
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$4,833,059
N01 · FY2018 · AI · contact PI